Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Proprotein Convertase Subtilisin/Kexin Type 9 Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 SX-PCK9
      • 1.3.3 O-304
      • 1.3.4 K-312
      • 1.3.5 BLSM-201
      • 1.3.6 DCRPCSK-9
      • 1.3.7 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2019-2025)
      • 1.4.2 Cardiovascular Disease
      • 1.4.3 Homozugous Familial Hyperchalesterolemia
      • 1.4.4 Liver Disease
      • 1.4.5 Metabolic Syndrome
      • 1.4.6 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size
      • 2.1.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue 2014-2025
      • 2.1.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales 2014-2025
    • 2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Growth Rate by Regions
      • 2.2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Regions 2014-2019
      • 2.2.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Manufacturers
      • 3.1.1 Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Manufacturers 2014-2019
      • 3.1.2 Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Manufacturers (2014-2019)
      • 3.2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Concentration Ratio (CR5 and HHI)
    • 3.3 Proprotein Convertase Subtilisin/Kexin Type 9 Price by Manufacturers
    • 3.4 Key Manufacturers Proprotein Convertase Subtilisin/Kexin Type 9 Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Proprotein Convertase Subtilisin/Kexin Type 9 Market
    • 3.6 Key Manufacturers Proprotein Convertase Subtilisin/Kexin Type 9 Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 SX-PCK9 Sales and Revenue (2014-2019)
      • 4.1.2 O-304 Sales and Revenue (2014-2019)
      • 4.1.3 K-312 Sales and Revenue (2014-2019)
      • 4.1.4 BLSM-201 Sales and Revenue (2014-2019)
      • 4.1.5 DCRPCSK-9 Sales and Revenue (2014-2019)
      • 4.1.6 Others Sales and Revenue (2014-2019)
    • 4.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Type
    • 4.3 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type
    • 4.4 Proprotein Convertase Subtilisin/Kexin Type 9 Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Application

    6 United States

    • 6.1 United States Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Company
    • 6.2 United States Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Type
    • 6.3 United States Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Application

    7 European Union

    • 7.1 European Union Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Company
    • 7.2 European Union Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Type
    • 7.3 European Union Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Application

    8 China

    • 8.1 China Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Company
    • 8.2 China Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Type
    • 8.3 China Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Company
    • 9.2 Rest of World Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Type
    • 9.3 Rest of World Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Application
    • 9.4 Rest of World Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Countries
      • 9.4.1 Rest of World Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Countries
      • 9.4.2 Rest of World Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 AFFiRiS AG
      • 10.1.1 AFFiRiS AG Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.1.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.1.5 AFFiRiS AG Recent Development
    • 10.2 Betagenon AB
      • 10.2.1 Betagenon AB Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.2.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.2.5 Betagenon AB Recent Development
    • 10.3 Bioleaders Corp
      • 10.3.1 Bioleaders Corp Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.3.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.3.5 Bioleaders Corp Recent Development
    • 10.4 BioLingus AG
      • 10.4.1 BioLingus AG Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.4.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.4.5 BioLingus AG Recent Development
    • 10.5 Catabasis Pharmaceuticals Inc
      • 10.5.1 Catabasis Pharmaceuticals Inc Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.5.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.5.5 Catabasis Pharmaceuticals Inc Recent Development
    • 10.6 Dicerna Pharmaceuticals Inc
      • 10.6.1 Dicerna Pharmaceuticals Inc Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.6.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.6.5 Dicerna Pharmaceuticals Inc Recent Development
    • 10.7 Eli Lilly and Co
      • 10.7.1 Eli Lilly and Co Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.7.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.7.5 Eli Lilly and Co Recent Development
    • 10.8 Ensemble Therapeutics Corp
      • 10.8.1 Ensemble Therapeutics Corp Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.8.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.8.5 Ensemble Therapeutics Corp Recent Development
    • 10.9 Kowa Co Ltd
      • 10.9.1 Kowa Co Ltd Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.9.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.9.5 Kowa Co Ltd Recent Development
    • 10.10 Novartis AG
      • 10.10.1 Novartis AG Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Proprotein Convertase Subtilisin/Kexin Type 9
      • 10.10.4 Proprotein Convertase Subtilisin/Kexin Type 9 Product Introduction
      • 10.10.5 Novartis AG Recent Development
    • 10.11 Pfizer Inc
    • 10.12 Regeneron Pharmaceuticals Inc
    • 10.13 Serometrix LLC
    • 10.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    • 10.15 The Medicines Company

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Proprotein Convertase Subtilisin/Kexin Type 9 Sales Channels
      • 11.2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Distributors
    • 11.3 Proprotein Convertase Subtilisin/Kexin Type 9 Customers

    12 Market Forecast

    • 12.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales and Revenue Forecast 2019-2025
    • 12.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales Forecast by Type
    • 12.3 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales Forecast by Application
    • 12.4 Proprotein Convertase Subtilisin/Kexin Type 9 Forecast by Regions
      • 12.4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Proprotein Convertase Subtilisin/Kexin Type 9 is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Proprotein Convertase Subtilisin/Kexin Type 9.

      This report studies the global market size of Proprotein Convertase Subtilisin/Kexin Type 9, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Proprotein Convertase Subtilisin/Kexin Type 9 sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      AFFiRiS AG
      Betagenon AB
      Bioleaders Corp
      BioLingus AG
      Catabasis Pharmaceuticals Inc
      Dicerna Pharmaceuticals Inc
      Eli Lilly and Co
      Ensemble Therapeutics Corp
      Kowa Co Ltd
      Novartis AG
      Pfizer Inc
      Regeneron Pharmaceuticals Inc
      Serometrix LLC
      Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
      The Medicines Company

      Market Segment by Product Type
      SX-PCK9
      O-304
      K-312
      BLSM-201
      DCRPCSK-9
      Others

      Market Segment by Application
      Cardiovascular Disease
      Homozugous Familial Hyperchalesterolemia
      Liver Disease
      Metabolic Syndrome
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Proprotein Convertase Subtilisin/Kexin Type 9 status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Proprotein Convertase Subtilisin/Kexin Type 9 manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Proprotein Convertase Subtilisin/Kexin Type 9 are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now